Idarubicin

Generic Name: Idarubicin

Brand Names: Idamycin

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₇NO_₉

CAS Number: 58957-92-9

Unique Ingredient Identifier: ZRP63D75JW

Background: An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

Indication: For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.

Associated Conditions: Acute Myeloid Leukemia

Associated Therapies: -

Clinical Trials

AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

Phase 4

Conditions: Leukemia, Promyelocytic, Acute

First Posted Date: 2005-09-16

Last Posted Date: 2011-07-11

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 80

Registration Number: NCT00180128

Locations: 🇩🇪
Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany

Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Idarubicin
Drug: Etoposide
Drug: Pegfilgrastim
Drug: All-trans retinoic acid

First Posted Date: 2005-09-08

Last Posted Date: 2017-09-20

Lead Sponsor: University of Ulm

Target Recruit Count: 920

Registration Number: NCT00151242

Locations: 🇩🇪
Clinical Center of Hematology and Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany
🇦🇹
Department of Hematology/Oncology, University Hospital Innsbruck, Innsbruck, Austria
🇩🇪
Department of Hematology and Oncology, Hospital Essen Süd, Ev. Hospital of Essen-Werden, Essen, Germany

and more 31 locations

All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

First Posted Date: 2005-09-08

Last Posted Date: 2017-04-19

Lead Sponsor: University of Ulm

Target Recruit Count: 500

Registration Number: NCT00151255

Locations: 🇦🇹
Department of Internal Medicine I, Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇩🇪
Medical Department I, Hospital of Bremen-Mitte, Bremen, Germany
🇩🇪
Department of Hematology and Oncology, Hospital Essen-Süd, Ev. Hospital of Essen-Werden, Essen, Germany

and more 26 locations

Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

First Posted Date: 2005-09-05

Last Posted Date: 2009-02-09

Lead Sponsor: University of Ulm

Target Recruit Count: 400

Registration Number: NCT00146120

Locations: 🇩🇪
I. Medical Department, City Hospital München-Schwabing, München, Germany
🇩🇪
Centre of Interial Medicine, University of Göttingen, Göttingen, Germany
🇩🇪
Medical Department III of Hematology and Oncology, General Hospital Altona, Hamburg, Germany

and more 19 locations

Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma

Phase 2

Conditions: Multiple Myeloma

First Posted Date: 2005-07-28

Last Posted Date: 2010-02-02

Lead Sponsor: University Hospital, Bonn

Target Recruit Count: 80

Registration Number: NCT00124813

Locations: 🇩🇪
Medical Clinic & Policlinic III, University of Bonn, Bonn, Germany

Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2005-04-06

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00107523

Locations: 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myelomonocytic Leukemia (M4)

Interventions: Drug: idarubicin
Drug: cytarabine
Other: laboratory biomarker analysis
Biological: bevacizumab

First Posted Date: 2004-11-09

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT00096148

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Myeloblastic Leukemia With Maturation (M2)
de Novo Myelodysplastic Syndromes
Untreated Adult Acute Myeloid Leukemia
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Pure Erythroid Leukemia (M6b)
Childhood Myelodysplastic Syndromes
Adult Acute Eosinophilic Leukemia
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)

Interventions: Drug: cytarabine
Drug: idarubicin
Drug: tipifarnib

First Posted Date: 2004-11-09

Last Posted Date: 2014-05-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT00096122

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2004-10-08

Last Posted Date: 2014-01-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 61

Registration Number: NCT00093483

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-09-16

Last Posted Date: 2013-05-30

Lead Sponsor: Loyola University

Registration Number: NCT00004905

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy